Drugs moving into the clinic: 5

By Mike Nagle

- Last updated on GMT

Related tags Immune system Merck serono

The fifth in a series of periodic roundups of drugs that have moved
from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
Sponsor Name Indication Mechanism
Argos Therapeutics AGS-004 HIV dendritic cells loaded with disease mRNA designed to induce immune response
ThromboGenics & BioInvent International TB-402 anti-coagulent human antibody designed to partially bind to Factor VIII and thus prevent coagulation but not increase the risk of bleeding side-effects
Adolor Corporation ADL5859 Pain management Delta opioid receptor agonist
Pharmacopeia PS433540 hypertension and diabetic nephropathy Dual-Acting angiotensin and endothelin Receptor Antagonist (DARA) - blocks action of two potent vasoconstrictor and mitogenic agents, angiotensin II (AII) and endothelin 1 (ET1), at their respective receptors
Merck Serono & Rigel R763 Oncology - acute or chronic myeloid leukemia (AML or CML) or myelodysplastic syndrome (MDS) multi-Aurora kinase inhibitor. NB. Phase I trial for solid tumours inititated Sept 2006
Transgene TG4040 (MVA-HCV) Hepatitis C Virus Vaccine expresses non structural proteins of the hepatitis C virus to induce an immune response

Related topics Preclinical Research

Related news

Show more

Follow us


View more